Cardiovascular Revascularization Medicine最新文献

{"title":"Serial quantitative optical coherence tomography for luminal volume changes following either paclitaxel or sirolimus coated balloon in de novo small coronary artery lesions.","authors":"Akihiro Tobe, Patrick Serruys, Kotaro Miyashita, Asahi Oshima, Pruthvi Chenniganahosahalli Revaiah, Tsung-Ying Tsai, Dijkstra Jouke, Scot Garg, Angela McInerney, Yoshinobu Onuma, Faisal Sharif","doi":"10.1016/j.carrev.2025.03.025","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.03.025","url":null,"abstract":"<p><strong>Background: </strong>Drug coated balloons (DCB) are a treatment option for lesions in small coronary arteries, with treatment using paclitaxel coated balloons (PCB) associated with less angiographic late lumen loss than sirolimus coated balloons (SCB).</p><p><strong>Methods: </strong>This single-center sub-study of the TRANSFORM-I study compared quantitative optical coherence tomography (OCT) data in patients with de novo lesions in small coronary arteries treated with the MagicTouch (SCB) or SeQuent Please Neo (PCB). The relationship between the lumen volume of the treated segment immediately post procedure and at 6-month follow-up was evaluated. Late lumen volume loss (LLVL, mm³) was defined as the post-procedural lumen volume - lumen volume at 6 months.</p><p><strong>Results: </strong>Serial OCT analysis was performed in 19 patients with 21 lesions (SCB: 9 patients/11 lesions; PCB: 10 patients/10 lesions). There was a significant decrease in lumen volume between post-procedure and 6 months in the SCB group (97.35 ± 71.09 mm³ vs 87.96 ± 61.48 mm³, p = 0.03), but not in the PCB group (69.67 ± 38.24 mm3 vs 71.64 ± 42.22 mm3, p = 0.64). The LLVL was 9.39 ± 12.76 mm³ and - 1.97 ± 12.90 mm³ in the SCB and PCB group, respectively (SCB vs PCB, p = 0.06). A trend for interaction between SCB and PCB was observed in the relationship between dissection volume and LLVL (SCB: LLVL = 1.28 ∗ dissection volume + 7.42, p = 0.37; PCB: LLVL = -2.84 ∗ dissection volume + 4.51, p = 0.12; p for interaction = 0.07).</p><p><strong>Conclusion: </strong>In de novo lesions of small coronary arteries, treatment with an SCB lead to a significant decrease in lumen volume at 6-months compared to post-procedure, with no significant change observed after treatment with a PCB.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter aortic valve replacement outcomes in patients with high gradient versus low ejection fraction low gradient severe aortic stenosis: A meta-analysis of randomized controlled trials","authors":"Asseel Al-Bayati ,&nbsp;Abdullah Alrifai ,&nbsp;Fahed Darmoch ,&nbsp;Haytham Alkhaimy ,&nbsp;Zaher Fanari","doi":"10.1016/j.carrev.2024.07.020","DOIUrl":"10.1016/j.carrev.2024.07.020","url":null,"abstract":"<div><h3>Background</h3><div>The outcome of Low Flow-Low Gradient (LF-LG) severe aortic stenosis (AS) patients who underwent Transcatheter Aortic Valve Replacement (TAVR) procedure is not well defined. We conducted a systematic review of the literature to compare the outcomes of TAVR in LF-LG AS patients to the more traditional high gradient (HG) aortic stenosis.</div></div><div><h3>Methods</h3><div>We comprehensively searched for controlled randomized and non-randomized studies from 4 online databases. We are presenting the data using risk ratios (95 % confidence intervals) and measuring heterogeneity using Higgins' I² index.</div></div><div><h3>Results</h3><div>Our analysis included 4380 patients with 3425 HG patients and 955 LF-LG patients from 6 cohort (5 retrospective and 1 prospective) studies. When compared to LFLG; TAVR was associated with significantly lower 30 days mortality in HG patients (5.1 % vs 7.4 %; relative risk [RR]: 0.55; 95 % confidence interval [CI]: 0.35 to 0.86; <em>p</em> &lt; 0.01). Similar findings were also observed in 12-month cardiovascular (CV) mortality (5.5 % vs. 10.4 %; RR: 0.47; 95 % CI: 0.38 to 0.60; p &lt; 0.01 and 12-month all-cause mortality (15.9 % vs 20.9 %; RR: 0.70; 95 % CI: 0.49 to 1.00; <em>p</em> &lt; 0.05). There was no significant difference in myocardial infarction (MI) after TAVR between HG and LF-LG at 30 days (0.16 % vs. 0.95 %; <em>p</em> &lt; 0.09) or 12 months (0.43 % vs. 0.95 %; <em>p</em> = 0.20). Similarly, there was no difference in stroke rates at 30 days (2.9 % vs. 2.86 %) or at 12 months (3.6 % vs. 3.06 %).</div></div><div><h3>Conclusions and relevance</h3><div>Patients with LF-LG severe AS who underwent TAVR had worse 1-year all-cause mortality, 30-day all-cause, and 1-year CV mortality when compared to TAVR in HG severe AS. There was no difference in MI or stroke rates. Therefore, with heart team discussion and informed patient decision regarding the risk and benefit, TAVR would still offer better outcomes in LFLG AS compared to conservative medical management.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 1-7"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of cardiac amyloidosis on outcomes in transcatheter aortic valve replacement in low-flow low-gradient aortic stenosis","authors":"Joseph Maenza ,&nbsp;Lakshay Chopra ,&nbsp;Carlo Mannina ,&nbsp;Esha Vaish ,&nbsp;Yash Prakash ,&nbsp;Johanna Contreras ,&nbsp;Francesca Prandi ,&nbsp;Ranbir Singh ,&nbsp;Parasuram Krishnamoorthy ,&nbsp;Sahil Khera ,&nbsp;George Dangas ,&nbsp;Gilbert H.L. Tang ,&nbsp;Samin K. Sharma ,&nbsp;Annapoorna S. Kini ,&nbsp;Stamatios Lerakis","doi":"10.1016/j.carrev.2024.11.008","DOIUrl":"10.1016/j.carrev.2024.11.008","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 82-84"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Old wine in new bottles","authors":"Spencer B. King III","doi":"10.1016/j.carrev.2025.04.010","DOIUrl":"10.1016/j.carrev.2025.04.010","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 107-108"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143891767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of contemporary methods to assess vessel specific myocardial mass","authors":"Atomu Tajima ,&nbsp;Nikolaos Stalikas ,&nbsp;Marta Belmonte ,&nbsp;Koshiro Sakai ,&nbsp;Nico Pijls ,&nbsp;Danielle C.J. Keulards ,&nbsp;Jeroen Sonck ,&nbsp;Patricio Astudillo ,&nbsp;Adriaan Wilgenhof ,&nbsp;Frederic Bouisset ,&nbsp;Daniel Munhoz ,&nbsp;Bernard De Bruyne ,&nbsp;Carlos Collet","doi":"10.1016/j.carrev.2024.11.011","DOIUrl":"10.1016/j.carrev.2024.11.011","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 85-87"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ST-elevation myocardial infarction from spontaneous coronary artery dissection with high thrombus burden","authors":"Hari P. Sritharan ,&nbsp;Adam C. Bland ,&nbsp;Thomas J. Ford ,&nbsp;Roberto Spina ,&nbsp;Michael Parkinson","doi":"10.1016/j.carrev.2024.10.013","DOIUrl":"10.1016/j.carrev.2024.10.013","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 88-90"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter aortic valve replacement with corevalve self-expanding bioprosthesis: Clinical and durability data up to 12 years","authors":"Luca Testa ,&nbsp;Cristina Giannini ,&nbsp;Giulia Costa ,&nbsp;Claudia Fiorina ,&nbsp;Marianna Adamo ,&nbsp;Mauro Massussi ,&nbsp;Giuseppe Bruschi ,&nbsp;Bruno Merlanti ,&nbsp;Matteo Montorfano ,&nbsp;Barbara Bellini ,&nbsp;Arnaldo Poli ,&nbsp;Erica Ferrara ,&nbsp;Antonio Sisinni ,&nbsp;Mattia Squillace ,&nbsp;Francesco De Felice ,&nbsp;Carmine Musto ,&nbsp;Alessandro Mazzapicchi ,&nbsp;Nedy Brambilla ,&nbsp;Tullio Palmerini ,&nbsp;Marco De Carlo ,&nbsp;Francesco Bedogni","doi":"10.1016/j.carrev.2024.07.013","DOIUrl":"10.1016/j.carrev.2024.07.013","url":null,"abstract":"<div><h3>Background and aims</h3><div>Transcatheter aortic valve replacement (TAVR) determined a paradigm shift in the treatment of patients with severe symptomatic aortic stenosis but data on very long-term durability are lacking. We sought to evaluate the clinical and hemodynamic outcomes of the CoreValve porcine pericardial self-expanding bioprosthesis at 12-year follow-up.</div></div><div><h3>Methods</h3><div>882 inoperable or high-risk patients were treated with the CoreValve bioprosthesis in 8 Italian high-volume centers between 2007 and 2011. The endpoints were 12-year all-cause and cardiovascular mortality, and Cumulative Incidence Functions (CIFs) for severe Structural Valve Deterioration (SVD), Bioprosthetic Valve Dysfunction (BVD), Bioprosthetic Valve Failure (BVF), and severe Hemodynamic Valve Deterioration (HVD). VARC-3 definitions were applied.</div></div><div><h3>Results</h3><div>Baseline characteristics included a mean age of 83 ± 6 years, and NYHA class III or IV in 76.3 % of patients. The actuarial risk of death at 12 years after TAVR was 95.5 % (CI 93.5 %- 97.1 %).</div><div>The actual risk of cardiovascular death, weighted against the risk of non-cardiac death at 12 years was 23.9 % (21.0 %–26.8 %). The 12-year actual risk of BVD was 7.0 % (5.3 %–8.9 %), of SVD was 3.6 % (2.5 %–5.2 %), of BVF was 3.12 % (2.02 %–4.57 %), and of severe HVD was 1.7 % (0.9 %–2.9 %). Mean transaortic gradient significantly decreased after the procedure (52 ± 15 mmHg vs 9 ± 5 mmHg, <em>p</em> &lt; 0.001), and remained stable up to 12 years (12 ± 4 mmHg, <em>P</em> = 0.08 vs. discharge).</div></div><div><h3>Conclusions</h3><div>The first-generation CoreValve bioprosthesis showed reassuring clinical and hemodynamic performance at 12-year follow-up.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 23-30"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restenosis rates for drug-eluting stents used in treating small vessel cardiac allograft vasculopathy after orthotopic heart transplantation","authors":"Malika Elhage Hassan ,&nbsp;Muzamil Khawaja ,&nbsp;Wissam A. Jaber ,&nbsp;Timothy Feliciano Fernandez ,&nbsp;Muhammad Asad Khan ,&nbsp;Elsa Hebbo ,&nbsp;Daniel Gold ,&nbsp;Bryan Kindya ,&nbsp;Divya Gupta ,&nbsp;William J. Nicholson ,&nbsp;Pratik Sandesara","doi":"10.1016/j.carrev.2024.07.006","DOIUrl":"10.1016/j.carrev.2024.07.006","url":null,"abstract":"<div><h3>Background</h3><div><span>Cardiac allograft vasculopathy<span> (CAV) is associated with increased mortality in patients with orthotopic heart transplantation (OHT). In addition to </span></span>immunosuppression<span><span>, CAV can be treated with percutaneous coronary intervention (PCI) with drug eluting stents (DES) for focal lesions. There is a paucity of data on the rate of DES </span>restenosis in patients with small vessel CAV.</span></div></div><div><h3>Methods</h3><div>This was a retrospective observational study of 101 coronary vessels treated with a DES diameter of 2.5 mm or less (small vessels) in 61 OHT patients compared to 72 coronary vessels treated with a DES diameter of &gt;2.5 mm (large vessels) in 44 OHT patients at a single center between 2004 and 2022. Baseline demographic data, angiographic characteristics, and clinical outcomes were analyzed.</div></div><div><h3>Results</h3><div><span>At an average of 1.6 years after DES placement<span><span>, follow-up angiography revealed in-stent </span>restenosis in 36 (39 %) small vessel interventions and 11 (17 %) large vessel interventions (</span></span><em>p</em> = 0.003). Long term mortality did not differ between the groups (59 % vs 59 % at a median of 4.7 [IQR 2.4–7.8] years follow up).</div></div><div><h3>Conclusion</h3><div>DES restenosis rates are high in small vessel CAV. Additional studies specifically examining PCI in small vessel CAV as well as the potential role for newer treatment strategies for CAV are warranted.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 64-69"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141708555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Correlation between fractional flow reserve and imaging findings during drug-coated balloon treatment for femoropopliteal diseases” [Cardiovascular Revascularization Medicine 60 (2024) 66–71]","authors":"Yoshihiro Iwasaki ,&nbsp;Takenobu Shimada ,&nbsp;Tatsushi Sato ,&nbsp;Jumpei Koike ,&nbsp;Atsushi Funatsu ,&nbsp;Tomoko Kobayashi ,&nbsp;Takanori Ikeda ,&nbsp;Shigeru Nakamura","doi":"10.1016/j.carrev.2024.06.005","DOIUrl":"10.1016/j.carrev.2024.06.005","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 109-110"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac output in patients with small annuli undergoing transcatheter aortic valve implantation with self-expanding versus balloon expandable valve (COPS-TAVI)","authors":"Muntaser Omari ,&nbsp;Taimurzeb Durrani ,&nbsp;Mario E. Diaz Nuila ,&nbsp;Alexandra Thompson ,&nbsp;Tim Irvine ,&nbsp;Richard Edwards ,&nbsp;Rajiv Das ,&nbsp;Azfar Zaman ,&nbsp;Mohamed Farag ,&nbsp;Mohammad Alkhalil","doi":"10.1016/j.carrev.2024.06.017","DOIUrl":"10.1016/j.carrev.2024.06.017","url":null,"abstract":"<div><h3>Background</h3><div>There is limited data on cardiac output in patients with small aortic annuli undergoing trans-catheter aortic valve implantation (TAVI) according to the implanted platform of balloon-expandable (BEV) compared to self-expanding valves (SEV).</div></div><div><h3>Methods</h3><div><span>This is a retrospective analysis of consecutive patients with severe aortic stenosis and small annuli who underwent successful TAVI. Cardiac output was measured using </span>echocardiography within 4 weeks following TAVI. Data were recorded and analysed by an experienced operator who was not aware of the type of the implanted valve.</div></div><div><h3>Results</h3><div>138 patients were included in the analysis, of whom 57 % underwent TAVI with BEV. Clinical and echocardiographic characteristics were comparable between the two platforms, except for more frequent previous cardiac surgery and smaller indexed aortic valve in the BEV group. There was no relationship between computed tomography-derived aortic annulus area and cardiac output post TAVI. When compared to patients who underwent TAVI with BEV, those with SEV had larger cardiac output [mean difference − 0.50 l/min, 95 % CI (−0.99, −0.01)] and cardiac index [mean difference − 0.20 l/min/m², 95 % CI (−0.47, 0.07)], although the latter did not reach statistical significance. Unlike patients with small body surface area, in those with large body surface area both cardiac output and cardiac index were statistically larger in patients who underwent SEV compared to BEV.</div></div><div><h3>Conclusion</h3><div>Cardiac output, as measured by echocardiography, was larger in patients with small annuli who underwent TAVI procedure with SEV compared to BEV. Such difference was more evident in patients with large body surface area.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 15-22"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}